Value
2.0/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.5 |
| Analyst target | 3.0 |
- ▸Expensive valuation
TWST · Why this verdict
Why Twist Bioscience (TWST) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.0/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Twist Bioscience is overbought with RSI at 72 and already 28% above analyst price targets, carrying 31% short interest and burning cash at 14% of revenue, while concentration in synthetic DNA products and a sole-source supplier create compounding risks.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The stock at $80.79 is 28% above the median analyst price target, with the nearest resistance at $81.33 and a stop loss at $75.13, producing negative asymmetry where downside to fair value is more than 30% while near-term upside is less than 1%. Warnings | Analyst price targets are revised upward to at least $100, restoring a positive reward-to-risk ratio above 1.5 from the current price. | →Stable |
| CounterIf the next earnings release substantially beats expectations again, as it did 3 of the last 4 quarters, analysts may quickly revise targets higher and close the gap. | ||
Both the primary product line, synthetic DNA, and the manufacturing supply chain rely on single-source arrangements, creating dual concentration risks where a product market disruption and a supply chain failure could simultaneously impair revenue and delivery. Bear case | At least one alternative supplier is qualified within the next 18 months, reducing single-supplier exposure for the core synthetic DNA product. | →Stable |
| CounterSingle-source manufacturing in synthetic biology is common and reflects the specialized nature of the equipment; the risk is real but typical for the industry rather than unique to Twist. | ||
A 31% short interest combined with cash burning at 14% of revenue means the stock faces both a fundamental constraint on how long it can operate without new financing and a structural ceiling from the large short position that will pressure any attempted rally. Key risks | Short interest falls below 18% within the next 12 months, reducing the structural selling pressure from short sellers. | →Stable |
| CounterA 31% short interest in a momentum stock with RSI at 72 creates significant short squeeze potential if the company announces a meaningful commercial partnership or product expansion. | ||
RSI at 72 with rising on-balance volume indicates the stock is technically overbought, a condition that historically increases the probability of a pullback, particularly when the stock is already trading well above analyst fair value estimates. Momentum breakdown | RSI normalizes below 55 without the stock price breaching the stop-loss at $75.13, signaling a healthy consolidation rather than a breakdown. | →Stable |
| CounterOverbought readings in high-momentum growth stocks can persist for extended periods if the underlying business momentum is strong, and the rising OBV confirms that buyers remain active at elevated levels. | ||
The stock at $80.79 is 28% above the median analyst price target, with the nearest resistance at $81.33 and a stop loss at $75.13, producing negative asymmetry where downside to fair value is more than 30% while near-term upside is less than 1%.
→StableWarnings
- Expectation
- Analyst price targets are revised upward to at least $100, restoring a positive reward-to-risk ratio above 1.5 from the current price.
CounterIf the next earnings release substantially beats expectations again, as it did 3 of the last 4 quarters, analysts may quickly revise targets higher and close the gap.
Both the primary product line, synthetic DNA, and the manufacturing supply chain rely on single-source arrangements, creating dual concentration risks where a product market disruption and a supply chain failure could simultaneously impair revenue and delivery.
→StableBear case
- Expectation
- At least one alternative supplier is qualified within the next 18 months, reducing single-supplier exposure for the core synthetic DNA product.
CounterSingle-source manufacturing in synthetic biology is common and reflects the specialized nature of the equipment; the risk is real but typical for the industry rather than unique to Twist.
A 31% short interest combined with cash burning at 14% of revenue means the stock faces both a fundamental constraint on how long it can operate without new financing and a structural ceiling from the large short position that will pressure any attempted rally.
→StableKey risks
- Expectation
- Short interest falls below 18% within the next 12 months, reducing the structural selling pressure from short sellers.
CounterA 31% short interest in a momentum stock with RSI at 72 creates significant short squeeze potential if the company announces a meaningful commercial partnership or product expansion.
RSI at 72 with rising on-balance volume indicates the stock is technically overbought, a condition that historically increases the probability of a pullback, particularly when the stock is already trading well above analyst fair value estimates.
→StableMomentum breakdown
- Expectation
- RSI normalizes below 55 without the stock price breaching the stop-loss at $75.13, signaling a healthy consolidation rather than a breakdown.
CounterOverbought readings in high-momentum growth stocks can persist for extended periods if the underlying business momentum is strong, and the rising OBV confirms that buyers remain active at elevated levels.
Per-dimension breakdown
Quality
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 6.4 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 9.1 |
| FCF quality | 0.0 |
| Moat | 7.2 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -14% of revenue
Growth
7.3/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 7.3 |
Momentum
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 0.7 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 2.5 |
| Analyst rating | 7.0 |
| Price target | 3.0 |
- ▸LLM news sentiment: -0.50 (n=1)
- ▸Light analyst coverage (10.0) — signal dampened
- ▸Below analyst target
Insider
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 3.8 |
| notable moves | 3.0 |
- ▸Notable insider selling — $15,300,427 (0.262% of mkt cap)
Peer rank
4.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.6 |
| quality rank | 1.3 |
| growth rank | 6.6 |
Technical
5.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 5.0 |
| support resistance | 4.0 |
| 52w position | 7.2 |
Risk (lower is worse)
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 0.0 |
| days to cover | 0.3 |
| volatility | 0.0 |
| put call | 3.3 |
| implied vol | 0.0 |
| max pain risk | 7.0 |
| beta | 3.0 |
| debt equity | 9.0 |
| news risk | 6.0 |
- ▸High short interest justified: 36%
- ▸High IV: 100%
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 3.5 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 4.9 |
| news activity | 5.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (5)
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:24d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:3.2<4.5
- ASYMMETRY:-1.7=NEGATIVE
Warning (1)
- INSIDER:0.26%=MODERATE
Reward-to-Risk
-1.69
Upside
-25.4%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 53 mid-range, Bollinger mid-band
EdgeCatalyst-Driven — Earnings in 24d with 3/4 beat streak
SuitabilityAggressive — Beta 2.12>1.3
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 3.2<4.5 outcome against Growth at 7.3 and asymmetric R:R of -1.69.
The strongest dimensions are Growth at 7.3, Technical at 5.4, and Catalyst at 5.0; the weakest are Value at 2.0, Insider at 3.0, and Risk (lower is worse) at 3.2. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of -1.69 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Severe Negative Asymmetry
Trip ifStock price drops below $70, more than 13% below the current $80.79, confirming breakdown from overbought levels to below analyst targets.
- P2Synthetic Dna Supplier Concentration
Trip ifA supply disruption reduces synthetic DNA product availability for more than 30 days, causing quarterly revenue to fall below $80 million.
- P3Cash Burn 31 Percent Short
Trip ifShort interest rises above 35% of the float or cash burn exceeds 20% of revenue for more than 2 consecutive quarters.
- P4Overbought Momentum Divergence
Trip ifRSI drops below 35 and price falls more than 15% from the current $80.79, signaling that the overbought condition has reversed into a breakdown.